DAIC

MARCH 26, 2025

Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA(finerenone) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Heart Failure 52

Heart Failure Preserved Ejection Fraction Kidney Disease ACE Inhibitor 52

CardiacWire

OCTOBER 6, 2024

Finerenone is already approved to reduce cardiovascular and kidney disease risks in patients with type 2 diabetes-associated CKD, but not for HF. The post Finerenone’s Early Heart Failure Impact appeared first on Cardiac Wire. in the future. And with a new drug, knowing which patients to target is a good way to start.

Heart Failure 59

Heart Failure Blood Pressure Kidney Disease Diabetes 59

DAIC

JANUARY 19, 2024

milla1cf Fri, 01/19/2024 - 10:55 January 19, 2024 — Orchestra BioMed , a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the first patient was randomized in the BACKBEAT pivotal study in late December 2023. Suman Pasupuleti, M.D. billion adults worldwide.

Pacemaker 105

Pacemaker Hypertension Blood Pressure Kidney Disease 105

DAIC

APRIL 9, 2024

UC Davis also hosted clinical trials for the procedure in 2023. “We Left untreated, tricuspid regurgitation can lead to atrial fibrillation , heart failure , kidney disease and even death. Food and Drug Administration (FDA) last week. Rogers , professor of cardiovascular medicine.

Tricuspid 111

Tricuspid Heart Valves Bicuspid/Mitral Quality of Life 111

Cardiometabolic Health Congress

JUNE 29, 2023

“We are pleased to announce our partnerships for the 2023 Women’s Cardiometabolic Health and Wellness Masterclass.

Peripheral Arterial Disease 40

Peripheral Arterial Disease Education Webinar Kidney Disease 40

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Hypertension Journal

OCTOBER 11, 2023

Hypertension, Volume 80, Issue 12 , Page 2591-2600, December 1, 2023. RESULTS:The median age of the patients was 76 years, and 54.9% were women. The total AHT incidence was 70 cases per 100 000 admission year. The absolute death rate increased from 1.83% (95% CI, 1.40–2.40) 2.40) to 2.88% ([95% CI, 2.42–3.41]; 2.06) to 2.60% (2.17–3.1;

Hypertension 40

Hypertension Kidney Disease Heart Failure Risk Factors 40

Stroke: Vascular and Interventional Neurology

NOVEMBER 9, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. 1.378]), and heart failure (1.282 [95%CI, 1.25‐1.315]).ConclusionPatient 1.378]), and heart failure (1.282 [95%CI, 1.25‐1.315]).ConclusionPatient

Risk Factors 40

Risk Factors Stroke Strokes Medicare 40

Cardiometabolic Health Congress

DECEMBER 7, 2023

Published on November 30, 2023, in the Journal of the American College of Cardiology, these new guidelines are based on a comprehensive literature review from May 2022 to November 2022, and provide important recommendations to clinicians caring for patients with or at risk of developing cardiovascular disease (CVD). J Am Coll Cardiol.

Atrial Fibrillation 111

Atrial Fibrillation Risk Factors Ablation Stroke 111

Circulation

NOVEMBER 10, 2023

Circulation, Volume 148, Issue 24 , Page 1982-2004, December 12, 2023. Cardiovascular-kidney-metabolic (CKM) syndrome is a novel construct recently defined by the American Heart Association in response to the high prevalence of metabolic and kidney disease.

Cardiovascular Disease 40

Cardiovascular Disease Heart Failure Kidney Disease Circulation 40

Frontiers in Cardiovascular Medicine

JANUARY 5, 2025

IntroductionVericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. Of these patients, 79.6% were male, with a mean age of 72.4 (SD:8.7) Of these patients, 79.6%

Heart Failure 52

Heart Failure Kidney Disease Blood Pressure Diabetes 52